Holen Sie sich die Stockscreener-App
17.81
2.52%
-0.46
Handel nachbörslich:
16.30
-1.51
-8.48%
Akari Therapeutics Plc Adr Aktie (AKTX) Neueste Nachrichten
VNET Group, Akari Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Akari Therapeutics Soars as KRAS ADC Data Triggers Rerating - timothysykes.com
Akari Therapeutics (AKTX) AGM June 30, 2026 — equity authorizations, warrants/ADSs - Stock Titan
Akari Therapeutics (NASDAQ: AKTX) sets $5.5M ADS and warrant private placement - Stock Titan
AKTX - Finviz
Keep an eye on the top gainers and losers in Friday's session. - ChartMill
Friday's session: gap up and gap down stocks - ChartMill
Discover the top movers in Friday's pre-market session. - ChartMill
Akari Therapeutics Announces $5.5 Million Private Placement Offering - Sahm
Dow Jumps 250 Points; BJ's Wholesale Shares Fall After Q1 Results - Sahm
Akari Therapeutics stock rockets 50% higher on KRAS combination data - Investing.com
Akari Therapeutics prices $5.5 million private placement By Investing.com - Investing.com South Africa
Akari Therapeutics prices $5.5 million private placement - Investing.com
Why Akari Therapeutics Stock Is Surging On Thursday? - Sahm
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
Akari Therapeutics secures European patent for ADC payload - Investing.com
Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets - Sahm
[S-1] Akari Therapeutics Plc Files IPO Registration Statement - Stock Titan
Debt to equity ratio of Akari Therapeutics Plc Sponsored ADR – MUN:CLA1 - TradingView
Unusual VolumeStock ScreenerNews - Finviz
Akari Therapeutics secures Australian patent for ADC payload By Investing.com - Investing.com South Africa
Akari Therapeutics secures Australian patent for ADC payload - Investing.com India
Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors - ChartMill
Maxim Sees High Risk Profile for Akari Therapeutics, plc (AKTX) Amid Capital Needs - Insider Monkey
Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing - ChartMill
Akari Therapeutics (NASDAQ: AKTX) registers 867,023 ADSs after ADS ratio change - Stock Titan
Akari Therapeutics PLC (FRA:CLA1) Stock Price, Trades & News - GuruFocus
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC - ChartMill
Total equity of Akari Therapeutics Plc Sponsored ADR – LSX:A4270Y - TradingView — Track All Markets
Long term debt to total assets ratio of Akari Therapeutics Plc Sponsored ADR – FWB:CLA1 - TradingView
Discontinued operations of Akari Therapeutics Plc Sponsored ADR – MUN:CLA1 - TradingView
Akari Therapeutics partners with WuXi XDC on ADC development By Investing.com - Investing.com India
Akari Therapeutics partners with WuXi XDC on ADC development - Investing.com
Top GainersStock ScreenerSnapshot - Finviz
Who's Buying or Selling Akari Therapeutics PLC (FRA:CLA1) Stock Today? - GuruFocus
Akari Therapeutics PLC (FRA:CLA1) Dividend - GuruFocus
Akari Therapeutics PLC (FRA:CLA1)Valuation Measures & Financial Statistics - GuruFocus
Akari Therapeutics PLC Stock Baskets | FRA:CLA1 - GuruFocus
Akari Therapeutics PLC Stock Operating Data - GuruFocus
Akari Therapeutics PLC (FRA:CLA1) Stock News, Headlines & Updates - GuruFocus
Akari Therapeutics PLC (FRA:CLA1) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Akari Therapeutics PLC (STU:CLA1) Stock News, Headlines & Updates - GuruFocus
Akari Therapeutics PLC (STU:CLA1) Valuation - GuruFocus
Akari Therapeutics PLC (STU:CLA1) Dividend - GuruFocus
Akari Therapeutics PLC Stock Baskets | STU:CLA1 - GuruFocus
Akari Therapeutics PLC (STU:CLA1)Valuation Measures & Financial Statistics - GuruFocus
Akari Therapeutics ADR: Dividend historical data and projections - marketscreener.com
Akari Therapeutics ADR: Revenue and Earnings Analysts Forecasts Revisions | AKTX | US00972G4055 - MarketScreener
Akari Therapeutics (NASDAQ: AKTX) sets ADS ratio to 1:80,000 in F-6/A filing - Stock Titan
Akari Therapeutics, Plc Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Akari Therapeutics (NASDAQ: AKTX) outlines ADC oncology strategy - Stock Titan
Short Interest in Akari Therapeutics PLC (NASDAQ:AKTX) Declines By 19.4% - Defense World
Akari Therapeutics revises ADS ratio to maintain Nasdaq compliance - MSN
Get insights into the top gainers and losers of Thursday's after-hours session. - ChartMill
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Akari Therapeutics Announces ADS Ratio Change, Reverse Split - The Globe and Mail
Akari Therapeutics adjusts ADS ratio to meet Nasdaq rules By Investing.com - Investing.com India
Akari Therapeutics adjusts ADS ratio to meet Nasdaq rules - Investing.com South Africa
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
Akari Therapeutics (NASDAQ: AKTX) plans 1-for-40 ADS ratio change to meet Nasdaq bid rules - Stock Titan
Director Neal James acquires Akari (AKTX) ADS warrants via placement and note swap - Stock Titan
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):